Apparent B-type natriuretic peptide selectivity in the kidney due to differential processing.

Area of Science:

• Cardiovascular Physiology
• Renal Physiology
• Endocrinology

Background:

• Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are key cardiac hormones involved in regulating blood pressure and fluid balance.
• The guanylyl cyclase-A (GC-A) receptor is the primary known receptor for both ANP and BNP signaling.

Purpose of the Study:

• To investigate the differential potency of ANP and BNP in mouse kidney cells.
• To elucidate the mechanisms underlying the observed differences in peptide activity within the kidney.
• To determine if a kidney-specific receptor or degradation pathway accounts for BNP's higher potency.

Main Methods:

• Experiments using mouse kidney cells and slices to measure cyclic GMP (cGMP) production in response to ANP and BNP.
• Utilizing mice genetically deficient in the GC-A receptor.
• Employing phosphoramidon, a neutral endopeptidase inhibitor, to assess peptide degradation.
• Mass spectrometry to analyze the stability and cleavage sites of ANP and BNP.

Main Results:

• Mouse BNP1-45 was significantly more potent (>50-fold) than ANP1-28 in increasing cGMP levels in kidney cells.
• In cells overexpressing GC-A, ANP and BNP showed similar potency, suggesting a kidney-specific factor influences their activity.
• Mice lacking the GC-A gene showed no significant cGMP elevation with either peptide in kidney slices.
• Phosphoramidon treatment normalized ANP's potency to BNP's level, indicating rapid ANP degradation in the kidney.
• Mass spectrometry confirmed ANP is rapidly cleaved, while BNP is stable, in kidney tissue.

Conclusions:

• The kidney exhibits specific and rapid degradation of ANP, but not BNP.
• This differential degradation mechanism allows BNP to preferentially regulate kidney function independently of systemic ANP levels.
• BNP's stability in the kidney contributes to its higher observed potency compared to ANP in this tissue.